Inteligencia IAMay 15, 2026Inteligencia IA
Artigo
TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results.
The company is developing novel therapies to overcome resistance to cancer immunotherapy.
Editorial Data Cube AIFonte: PR Newswire
01
Brief da fonte
TuHURA Biosciences, an immuno-oncology company, released Q1 2026 financial results. The company is developing novel therapies to overcome resistance to cancer immunotherapy.
02